araag2/HINT huggingface dataset:
Clinical trial NCT02934828 (phase 2, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: neoadjuvant chemotherapy, postoperative chemotherapy
SMILES: CCC1=C2CN3C(=CC4=C(COC(=O)[C@]4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(CC3)N3CCCCC3)C=C12, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          1. Invasive breast cancer confirmed by pathology evaluation of core biopsy

          2. Tumors must be ER/PgR status negative (immunohistochemistry（IHC） < 10%) and lack of
             HER2/neu overexpression or amplification as measured by local hospital pathology
             laboratory (IHC +/- fluorescence in situ hybridization (FISH) and IHC < 3+, and FISH <
             2.2) as described in the NCCN Guidelines

          3. Female between18 to 70 years of age, Eastern Cooperative Oncology Group(ECOG)
             Performance Status 0 or 1

          4. Early-stage TNBC or HER2 positive breast cancer according to the American Joint
             Committee on Cancer (AJCC) Staging Manual Clinical Stage IIA or IIB, Stage IIIA
             operable breast cancer

          5. Previously untreated

          6. Adequate hematologic function (absolute neutrophil count ≥ 1,500 cells/µL; hemoglobin
             > 9 g/dL, platelets > 100,000/µL.)

          7. Adequate hepatic function: total bilirubin ≤ upper limit of normal (ULN), serum
             albumin ≥≥ 3.0 g/dL, alanine aminotransferase and aspartate aminotransferase ≤ 1.5 x
             ULN.

        Exclusion Criteria:

          1. ICH:ER/PgR status positive

          2. HER2 positive breast cancer Patients with reduced ejection fraction <50% are not
             eligible

          3. Patients with second malignancies

          4. Patients with bilateral breast cancer

          5. allergic constitution
Clinical trial NCT02935101 (phase 2, status: terminated)
Conditions: opioid dependence, cocaine dependence
ICD codes: F11.20, F11.24, F11.281, F11.282, F11.288, F11.29, F11.21, F14.20, F14.24, F14.280, F14.281, F14.282, F14.288, F14.29
Drugs: prednisolone, placebo (for prednisolone)
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    difficulties in recruiting study participants
  
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent as documented by signature,

          -  age ≥18,

               -  Group A Detoxification of stimulants (cocaine, amphetamine and/or
                  methamphetamine); ICD-10: F14.2 and/or F15.2) OR Stable opioid dependency (no
                  parallel consumption). Detoxifica-tion of stimulants.

               -  Group B Opioid dependency and dependency of stimulants (cocaine, amphetamine
                  and/or methamphetamine) and Detoxification of parallel consumption of stimulants
                  and heroin (ICD-10: F11.2, 14.2, 15.2)

          -  admission for detoxification to ward U2 of the University Psychiatric Hospital of
             Basel

        Exclusion Criteria:

          -  contraindications to the class of drugs under study or to any of the excipients, e.g.
             known hypersensitivity or allergy to class of drugs or the investigational product;

          -  acute or severe co-morbid psychiatric disturbances (such as a heavy episode of major
             depression with suicidal ideations, acute exacerbation of a bipolar disorder, acute
             exacerbation of schizophrenia, alcohol addiction with an acute relapse, psychosis,
             dementia);

          -  current medical conditions excluding participation (such as acute infectious disease,
             moni-tored by elevated CRP, diabetes mellitus, anticoagulation therapy);

          -  recent history of systemic or topic glucocorticoid therapy;

          -  alcohol intake > 0.0 ‰ according to breathalyser test on day 0 (screening) to exclude
             severe alcohol abuse;

          -  specific drugs not allowed during the study or for specific periods of time prior to
             the administration of the test dose: Anticoagulant agents, antidiabetic agents,
             cyclosporine;

          -  women who are pregnant or breast feeding;

          -  intention to become pregnant during the course of the study;

          -  inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia;

          -  participation in another study with investigational drug within the 30 days preceding
             or during the present study;

          -  previous enrolment into the current study;

          -  enrolment of the investigator, his/her family members, employees and other dependent
             persons.
Clinical trial NCT02939391 (phase 2, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: kw-6356, kw-6356, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject fulfills the UK Parkinson's Disease Society brain bank clinical diagnostic
             criteria

          -  Parkinson's disease patients in Stages 1 to 3 on the Modified Hoehn and Yahr Scale

          -  MDS-UPDRS part III score of ≥ 15

        Exclusion Criteria:

          -  Use of any CYP3A4/5-related drugs within 2 weeks prior to enrollment.

          -  Use of any of the specified antiparkinsonian drugs and dopamine antagonists during the
             specified period.

          -  Treatment with levodopa/DCI at any time in the past for a period of 4 weeks or more.

          -  Neurosurgical operation for Parkinson's disease (stereotactic surgery, deep brain
             stimulation or gamma knife), or treatment by transcranial magnetic stimulation (TMS).

          -  Either of the following criteria consecutively at screening and enrollment;

               -  Resting Pulse > 100 bpm

               -  Resting systolic blood pressure > 140 mmHg, or diastolic blood pressure > 90 mmHg

          -  Significant dementia or a Mini-Mental State Examination (MMSE) score of ≤ 23.

          -  Subject has a history or evidence of suicidal ideation (severity of 4 or 5) or any
             suicidal behavior based on an assessment with the Columbia-Suicide Severity Rating
             Scale (C-SSRS) at baseline.

          -  Anyone otherwise considered unsuitable for the study by the investigator or
             sub-investigator including those who are unable to communicate or to cooperate with
             the investigator or sub-investigator.
Clinical trial NCT02940626 (phase 2, status: terminated)
Conditions: pneumonia, ventilator-associated, pneumonia, staphylococcal
ICD codes: J95.851, G00.3, M00.09, A05.0, M00.08, L00, M00.00, M00.011
Drugs: asn100, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    as a result of a pre-planned interim analysis for futility
  
Eligibility criteria:

        Inclusion Criteria:

        - Subject is currently hospitalized and is mechanically ventilated endotracheally (i.e.,
        orotracheal or nasotracheal) and, in the Investigator's opinion, will require ongoing
        ventilator support for at least 48 hours;

        Exclusion Criteria:

          -  Subject has a chest X-ray or thoracic computed tomography (CT) scan that is definitive
             for a diagnosis of pneumonia

          -  Subject has a known and documented ETA culture showing heavy colonization with a
             -Gram-negative organism at enrollment or at any time during the Screening period;

          -  Significant Neutropenia

          -  Severe non-pulmonary source of infection.

          -  Subjects with a known history or current (suspected) diagnosis of cytokine release
             syndrome associated with the administration of peptides, proteins, and/or antibodies.
Clinical trial NCT02943720 (phase 2, status: completed)
Conditions: allergic rhinitis
ICD codes: J30.89, J30.9, J30.2, J30.1, J30.5, J30.81
Drugs: allert, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects 18 to 65 yrs old, male or female

          -  moderate to severe allergic Rhinitis/Rhinoconjunctivitis to birch pollen during the
             two preceding birch pollen seasons

          -  positive Skin Prick Test (SPT) to birch pollen extract

          -  positive specific IgE CAP to Bet v1.

        Exclusion Criteria:

          -  persistent non-controlled asthma (Forced Expiratory Volume, FEV1 < 85% of predicted),

          -  previous specific immunotherapy (SIT) to tree pollens,

          -  previous SIT to any allergen within 5 years,

          -  previous history of severe anaphylactic reaction,

          -  perennial allergic Rhinitis/Rhinoconjunctivitis,

          -  other disorder possibly influencing the trial outcomes,

          -  pregnancy,

          -  any severely debilitating disease,

          -  primary or secondary immunodeficiency or treatment with immunosuppressor drugs within
             one month prior to randomization (oral steroids, other immunosuppressors).
Clinical trial NCT02945852 (phase 2, status: unknown status)
Conditions: small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: apatinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        Histologic or cytologic diagnosis of small cell lung caner(SCLC), Extensive Stage.

        Previous treatments including first-line therapy with EP or CE and second-line therapy with
        topotecan; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; Males or
        females between 18 Years to 75 Years. Expected survival is above three months. At least one
        measurable lung tumor lesion (according to RECIST criteria, the application of conventional
        technology, diameter length of the lesion >= 20mm or spiral CT >=10mm).

        Adequate hematologic (Leukocyte count >= 4.0×109/L, neutrophil count>=2.0×109/L,
        hemoglobin>=95g/L, platelets>=100×109/L), hepatic function (aspartate transaminase (AST) &
        alanine transaminase(ALT) =<upper normal limit(UNL) x1.5, bilirubin level =< UNL x 1.5).

        Patient can take oral medicine. Patients have the ability to understand and voluntarily
        sign the informed consent, and allow adequate follow-up.

        Exclusion Criteria:

        History of cardiovascular disease: congestive heart failure (CHF) > New York Heart
        Association (NYHA) II, active coronary artery disease(patients with myocardial infarction
        six months ago can be recruited), arrhythmias need to be treated (allow taking beta
        blockers or digoxin).

        Serious clinical infection (> NCI-CTCAE version 4.0 ,infection standard II). Patients with
        epilepsy who need to take medicine (such as steroids or anti epilepsy agents).

        The patients had accepted allogeneic organ transplantation. Bleeding tendency or
        coagulation disorders. Patients who need renal dialysis. Suffered from other tumor within 5
        years( Except: cervical carcinoma in situ, cured basal cell carcinoma, cured bladder
        epithelial tumor).

        Uncontrolled hypertension (systolic pressure>150 mmHg , or diastolic pressure> 90 mmHg).

        Thrombosis or embolism(cerebrovascular accidents including transient ischemic attack within
        the last 6 months).

        Pulmonary hemorrhage >CTCAE grade 2 within 4 weeks before first use of drugs. Other organ
        hemorrhage >CTCAE grade 3 within 4 weeks before first use of drugs. severe uncured wounds,
        ulcers or fracture. uncured dehydration. Factors influencing the safety and compliance of
        patients. Inability to comply with protocol or study procedures. Pregnant or
        breast-feeding. The researcher believe that the Patient is not suitable to participate in
        the study.
Clinical trial NCT02947048 (phase 2, status: completed)
Conditions: autism
ICD codes: Z13.41
Drugs: l1-79, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males who are not sexually active

          2. 13 and 21 years of age

          3. Signed informed consent

          4. Normal clinical laboratory values

          5. DSM-5 compliant diagnosis of autism spectrum disorder, confirmed by the Autistic
             Diagnosis Interview Review (ADIR), and by the Autism Diagnosis Observation Schedule
             (ADOS) score consistent with a diagnosis of autism

          6. No more than one concomitant medication for the treatment of autism, on a stable for
             at least 2 weeks prior to enrollment and no planned changes in psychosocial
             interventions during the trial

          7. No medications for any other pathology

        Exclusion Criteria:

          1. Any co-morbidities, including Fragile-X syndrome, epilepsy, Retts syndrome, ADHD, or
             other disease or syndrome aside from autism that requires treatment

          2. Any other psychiatric disorder, or out of range lab values

          3. DSM-5 diagnosis of schizophrenia, schizoaffective disorder, alcohol use disorder

          4. Active medical problems: unstable seizures (>2 in past month)

          5. Concomitant physical illness
Clinical trial NCT02947880 (phase 2, status: withdrawn)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: bumetanide, placebo
SMILES: CCCCNC1=C(OC2=CC=CC=C2)C(=CC(=C1)C(O)=O)S(N)(=O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the recently feasibility study shows that the number of patients is insufficient in the centers
  
Eligibility criteria:

        Inclusion Criteria:

          -  Children and teenager from age 5 to age 17, with a diagnosis of typical autism or
             Asperger syndrome according to the criteria of diagnosis of the WHO's classification
             (CIM-10),

          -  With a known etiology,

          -  Patients for whom the CARS results are strictly Superior or equal to 30,

          -  Of whom the parents have given their free, informed and written consent,

          -  Affiliated or beneficiary of the French social security.

        Exclusion Criteria:

          -  Patients under treatment by inlet diuretic either at the time of the study or before,

          -  Patients with electrolytic disorders,

          -  Patients with a known hypersensitivity to sulfa drugs,

          -  Patients with a hepatic or renal failure,

          -  Patients with an epilepsy not controlled by a treatment (comitial crisis in the past 6
             month at the time the trial starts despite a treatment),

          -  Patients under treatment by psychotropic exception made of the melatonin,

          -  Allergy to the bumetanide or one of its excipients,

          -  Patient under a treatment by lithium, diphemanil, erythromycin IV, halofantrine,
             pentamidine, sultopride, vincamine, aminoglycoside,

          -  Pregnant and lactating women.

        Secondary exclusion criteria:

          -  QT prolongation noticed on the ECG at Day0,

          -  Anomaly on the biological check up (Day 0) made before including the patient that
             would contraindicated the prescription of bumetanide,

          -  Patients for whom the CARS results are strictly inferior to 30.
Clinical trial NCT02949843 (phase 2, status: terminated)
Conditions: egfr activating mutation, recurrent non-small cell lung carcinoma, stage iv non-small cell lung cancer
ICD codes: D68.52, J84.83, D02.20, D02.21, D02.22, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: chemotherapy, targeted molecular therapy, tyrosine kinase inhibitor
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CC1=CC=C(O)C=C1)C(O)=O
Reason stopped: 
    slow accrual, closed by irb
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed incurable non-small cell
             lung cancer that harbors an activating mutation in EGFR, MET, BRAF, V600E, RET, HER2,
             translocation in Alk, or translocation in ROS-1

          -  Patients must be receiving treatment or planning to start treatment with a tyrosine
             kinase inhibitor targeting the activated gene

          -  Patients may not be receiving the treatment targeting the activated gene as part of a
             clinical treatment trial other than the Precision Oncology Trial

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-3

          -  Total bilirubin =< 1.5 X institutional upper limit of normal

          -  Aspartate transaminase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine
             transaminase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X
             institutional upper limit of normal

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control) prior to study entry and for the
             duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Ability to understand and the willingness to sign an Institutional Review Board
             (IRB)-approved informed consent document

        Exclusion Criteria:

          -  Emergent need for palliative radiation

          -  Patients may not be receiving any other investigational agents for the treatment of
             non-small cell lung cancer

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded; breastfeeding should be discontinued
Clinical trial NCT02950480 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: zafirlukast
SMILES: COC1=CC(=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2)C(=O)NS(=O)(=O)C1=CC=CC=C1C
Reason stopped: 
    low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients who are scheduled to undergo therapeutic or prophylactic mastectomy with
             immediate placement of tissue expanders and have a strong family history or hereditary
             cancer

          2. Age ≥ 18 years

          3. Zafirlukast is pregnancy category B. There are no adequate and well-controlled trials
             in pregnant women. Therefore, the effects of zafirlukast on the developing human fetus
             are unknown. For this reason, women of child-bearing potential must agree to use
             adequate contraception: 2 methods of birth control, prior to study entry ad for the
             duration of study participation. Should a woman become pregnant or suspect she is
             pregnant while she is participating in this study, she should inform her treating
             physician immediately.

          4. Ability to understand a written informed consent document, and the willingness to sign
             it

          5. At least 4 weeks post-completion of chemotherapy

          6. Adequate organ function within 14 days start of study start:

               1. Absolute neutrophil count (ANC) ≥ 1.5 X 10^9/L

               2. Hemoglobin (Hgb) ≥9g/dL

               3. Platelets (plt) ≥ 100 x 10^9/L

               4. Potassium within normal range, or correctable with supplements;

               5. AST and ALT ≤2.5 x Upper Limit Normal (ULN) or ≤5.0 x ULN if liver tumor is
                  present;

               6. Serum total bilirubin ≤ 1.5 x ULN

               7. Serum creatinine ≤ 1.5 x ULN, or 24-hr clearance ≥ 60ml/min

        Exclusion Criteria:

          1. Any significant medical condition, laboratory abnormalities, which places the subject
             at unacceptable risk if he/she were to participate in the study

          2. Currently on a leukotriene inhibitor or used within the past 6 months

          3. Prior chest wall radiation

          4. Pregnant or breastfeeding

          5. Hepatic impairment as defined by:

             • AST(SGOT) > 2.5X institutional ULN and ALT(SGPT) > 2.5X institutional ULN

          6. Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the trial.
Clinical trial NCT02956226 (phase 2, status: completed)
Conditions: autistic disorder
ICD codes: F84.0
Drugs: cannabinoids - 99% pure cannabinoids mix, placebo, cannabinoids - whole plant extract
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria: (both are needed)

          -  ASD diagnosis (Diagnostic and Statistical Manual of Mental Disorders [Fifth Edition;
             DSM-V]

          -  Moderate or greater behavioral problems as measured by a rating of moderate or higher
             (≥4) on the Clinical Global Impression-Severity (CGI-S)

        Exclusion Criteria:

          -  Planned changes in existing interventions for the duration of the trial or such a
             change in the last 4 weeks.

          -  Current treatment with cannabis based therapy or such a treatment in the last 3
             months.

          -  Heart, liver, renal or hematological disorders

          -  History of psychotic disorder in a first degree relative.